Voyageur Minerals retains Frontier Merchant Capital Group for marketing and financial communication services
07 Novembro 2019 - 7:35PM
Voyageur Minerals Ltd. (TSX.V:VM) (the
“
Company” or “
Voyageur”) is
pleased to announce that it has retained the services of Frontier
Merchant Capital Group ("FronTier") to provide marketing and
financial communications services. FronTier is an investor
relations and marketing group with a home office in Toronto,
Canada. FronTier will assist the company by increasing market
awareness for the company using a number of financial market
communications initiatives, including facilitating in-person
introductions for the company with retail brokers, institutional
advisors and life Sciences/ Pharmaceutical focussed industry
analysts, in Toronto and other financial capitals, and through
media distribution on national television, radio and multiple
on-line channels.
Under the terms of the engagement, FronTier has
been retained for a 12-month period at CAD $90,000 (plus applicable
sales tax) per annum plus direct expenses. The company will also
grant 100,000 stock options to the Frontier team at exercisable at
price of $0.10 expiring 2 years from date of grant.
About Voyageur
Voyageur Minerals Ltd. is a Canadian public
company listed on the TSX Venture Exchange under the trading symbol
VM. Voyageur is focused on the development of Active Pharmaceutical
Ingredients (API) minerals. The current focus is developing barite
and Iodine radiocontrast products and developing Bromine based
pharmaceutical products.
Voyageur’s goal is to generate positive cash
flow from operations through its recently signed joint venture with
Chief Medical Supply Ltd. – Alberta’s only pharmaceutical
manufacturer. The joint venture contemplates turnkey
manufacturing, bottling and distribution of Barium
radiopharmaceuticals for MRI, X-ray and CT scan applications. The
Company also contemplates a similar Health Canada registration
application for Iodine and Bromine products also for medical
applications.
Voyageur owns 100% interest in three barium
sulfate ("Barite") deposits including two properties suitable in
grade for the industrial barite market place, including interests
in a high-grade iodine, lithium & bromine brine project in
Utah, USA.
For further information, please contact:
Steven R. LivingstonCell: (403) 471-1659Office:
(587)-779-6166steve@voyageurminerals.cawww.voyageurminerals.ca
Reader Advisory
Neither the TSXV nor its Regulation
Services Provider (as that term is defined in the policies of the
TSXV) accepts responsibility for the adequacy or accuracy of this
news release. Cautionary Note Regarding Forward-Looking
Statements:
This news release contains certain statements or
disclosures relating to the Company that are based on the
expectations of its management as well as assumptions made by and
information currently available to the Company which may constitute
forward-looking statements or information ("forward-looking
statements") under applicable securities laws. All such statements
and disclosures, other than those of historical fact, which address
activities, events, outcomes, results or developments that the
Company anticipates or expects may or will occur in the future (in
whole or in part) should be considered forward-looking statements.
In some cases, forward-looking statements can be identified by the
use of the words "will", "intend," “anticipates”, “plans” and
similar expressions.
In particular, but without limiting the
foregoing, this news release contains forward-looking statements
pertaining to anticipated registrations with Health Canada for
various pharmaceutical products the Company’s plan to develop,
produce and sell certain products, and anticipated cash
flows. Although Voyageur believes that expectations and
assumptions on which the forward-looking statements and information
are based are reasonable, undue reliance should not be placed on
the forward-looking information and statements because Voyageur
cannot give any assurances that they will prove to be correct.
Forward-looking statements are based on the opinions and estimates
of management of management at the date hereof and are subject to a
variety of risks and uncertainties and other factors that could
cause actual events or results to differ materially from those
projected in the forward-looking statements, including but not
limited to expectations and assumptions concerning the
registrations of ImagingX’s products with Health Canada and the
ability to obtain the benefits thereof, the ability of the Company
to produce barite from its mineral properties for the key
ingredient for ImagingX’s Barium products and delays or changes in
plans with the joint venture partner. The Company cannot assure
that actual results will be consistent with these forward-looking
statements.
The forward-looking statements contained in this
news release are made as of the date hereof and the Company
undertakes no obligations to update publicly or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, unless so required by applicable
securities laws.
Voyageur Pharmaceuticals (TSXV:VM)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Voyageur Pharmaceuticals (TSXV:VM)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024